한글목차

외음부통 치료 세계 시장은 2024년에 445억 8,000만 달러로 평가되며, 예측 기간 동안 8.38%의 CAGR을 기록하여 2030년까지 722억 6,000만 달러에 달할 것으로 예상됩니다.

외음부통은 외음부에 영향을 미치는 만성적인 통증 증상으로, 종종 작열감, 찌르는 듯한 통증, 자극감 또는 따끔거림이 특징입니다. 주로 가임기 여성에게 발병하며, 서서히 발병하기도 하고 갑자기 발병하기도 합니다. 정확한 원인은 밝혀지지 않았지만 호르몬의 변동, 감염, 신경 손상 등이 원인으로 추정됩니다. 진단은 일반적으로 병력 청취, 신체 검사, 전문적 평가, 다른 잠재적 원인을 배제하기 위해 병력 청취, 신체 검사, 전문적 평가가 결합되어야 합니다. 치료 옵션은 다양하며, 외용제 및 내복약, 물리치료, 상담, 심한 경우 외과적 수술 등 다양한 치료법이 있습니다. 외음부통에 대한 인식의 증가, 진단 도구의 개선, 치료 옵션의 발전이 시장을 크게 견인하고 있습니다. 원격의료와 산부인과 의사, 물리치료사, 통증 전문가, 정신건강 전문가를 통합하는 다학제적 치료 접근법의 채택이 증가하고 있는 것도 시장 성장을 더욱 촉진하고 있습니다. 또한, 기술 혁신에 힘입어 보다 효과적이고 표적화된 치료법에 대한 연구가 진행되면서 전 세계적으로 외음부통 환자들의 개별화된 치료에 대한 접근성이 확대되고 있습니다.

주요 시장 촉진요인

기술 발전

주요 시장 과제

제한된 치료 옵션

주요 시장 동향

환자 중심의 의료

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 외음부통 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(바이오피드백·물리치료, 병변내 주사, 경구 치료, 외과 치료, 국소 치료)
  • 적응증별(전신성 외음부통, 국소성 외음부통)
  • 프로바이더별(병원·요양시설, 제약·바이오테크놀러지 기업, 연구개발 센터)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 외음부통 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 외음부통 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 외음부통 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 외음부통 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 외음부통 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 세계의 외음부통 치료 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Novartis AG
• Endo International Inc
• Teva Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd
• Cipla Inc
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Abbvie Inc
• Zydus Group
• Taro Pharmaceutical Industries Ltd

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

영문목차

The Global Vulvodynia Treatment Market was valued at USD 44.58 billion in 2024 and is projected to reach USD 72.26 billion by 2030, registering a CAGR of 8.38% during the forecast period. Vulvodynia is a chronic pain condition affecting the vulvar region, often characterized by burning, stinging, irritation, or rawness. It primarily affects women of reproductive age and can develop gradually or suddenly. While the exact cause remains unclear, contributing factors may include hormonal fluctuations, infections, or nerve injury. The diagnosis typically involves ruling out other potential causes through a combination of medical history review, physical examinations, and specialized assessments. Treatment options are diverse, encompassing topical and oral medications, physical therapy, counseling, and surgical procedures in severe cases. The growing awareness of vulvodynia, improved diagnostic tools, and advances in therapeutic options are significantly driving the market. Increasing adoption of telemedicine and multidisciplinary care approaches-integrating gynecologists, physiotherapists, pain specialists, and mental health professionals-further supports market growth. Additionally, research into more effective and targeted therapies, supported by technological innovation, is expanding access to personalized care for vulvodynia patients globally.

Key Market Drivers

Technological Advancements

Technological innovations are playing a pivotal role in advancing the diagnosis and treatment of vulvodynia. High-resolution imaging tools such as MRI and ultrasound are increasingly used to assess pelvic anatomy and guide clinical decisions. The rise of telemedicine-particularly following the COVID-19 pandemic-has expanded access to specialist care for vulvodynia patients, especially those in remote areas. Additionally, artificial intelligence (AI) tools are being developed to assist in diagnosis by analyzing clinical data and identifying patterns indicative of vulvodynia. Other notable advancements include biofeedback and electrical stimulation devices used in pelvic floor therapy, targeted drug delivery systems (such as medicated topical creams), and mobile health apps for symptom tracking and patient education. Furthermore, wearable technologies and virtual reality interventions are emerging to help patients manage pain and monitor therapy effectiveness. These innovations are enhancing clinical outcomes and promoting a patient-centric approach to care, fueling the overall growth of the vulvodynia treatment market.

Key Market Challenges

Limited Treatment Options

A major challenge in the vulvodynia treatment market is the limited availability of effective, standardized therapies. Due to the condition's complex and varied nature, patients often undergo a lengthy trial-and-error process to find relief. Treatment outcomes can vary widely among individuals, and medications such as anticonvulsants, antidepressants, or topical anesthetics may not deliver consistent or lasting results. Moreover, some of these drugs can cause adverse effects, complicating the treatment process. Access to non-pharmacological therapies like pelvic floor physical therapy and cognitive behavioral therapy is also inconsistent, particularly in rural or underserved regions. Compounding these issues is the lack of comprehensive understanding of the condition's etiology, which hampers innovation in targeted drug development. Inadequate funding and limited awareness among healthcare providers further delay diagnosis and effective treatment. This shortage of robust treatment options often impacts patients' mental well-being, underscoring the urgent need for broader access to specialized care and research-backed interventions.

Key Market Trends

Patient-Centered Care

The shift toward patient-centered care is becoming a key trend in the vulvodynia treatment market. Healthcare providers are increasingly emphasizing personalized treatment strategies that address not only the physical symptoms but also the psychological and emotional impact of chronic vulvar pain. This approach includes shared decision-making, where patients actively participate in choosing treatment plans tailored to their preferences and lifestyle. Education is also central to this model-patients are encouraged to understand their condition and engage in self-management techniques, such as lifestyle changes and therapy adherence. Multidisciplinary support-including physical therapy, pain management, and mental health services-is integrated to offer a holistic treatment pathway. Additionally, providers are more attuned to patient feedback and committed to respecting individual treatment choices, even when they involve complementary or alternative therapies. By focusing on empowering patients, this trend is improving satisfaction, adherence, and overall health outcomes in vulvodynia care.

Key Market Players

• Novartis AG
• Endo International Inc
• Teva Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd
• Cipla Inc
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Zydus Group
• Taro Pharmaceutical Industries Ltd
• Abbvie Inc.

Report Scope:

In this report, the Global Vulvodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvodynia Treatment Market, By Type:

• Biofeedback & Physical Therapy
• Intralesional Injections
• Oral Treatment
• Surgical Treatment
• Topical Treatments

Vulvodynia Treatment Market, By Indication:

• Generalized Vulvodynia
• Localized Vulvodynia

Vulvodynia Treatment Market, By Providers:

• Hospitals & Care Providers
• Pharmaceutical & Biotechnology Companies
• Research & Development Centers

Vulvodynia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvodynia Treatment Market.

Available Customizations:

Global Vulvodynia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vulvodynia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment, Surgical Treatment, Topical Treatments)
  • 5.2.2. By Indication (Generalized Vulvodynia, Localized Vulvodynia)
  • 5.2.3. By Providers (Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies, Research & Development Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Vulvodynia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Providers
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Vulvodynia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Providers
  • 6.3.2. India Vulvodynia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Providers
  • 6.3.3. Australia Vulvodynia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Providers
  • 6.3.4. Japan Vulvodynia Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Indication
      • 6.3.4.2.3. By Providers
  • 6.3.5. South Korea Vulvodynia Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Indication
      • 6.3.5.2.3. By Providers

7. Europe Vulvodynia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Providers
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Vulvodynia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Providers
  • 7.3.2. Germany Vulvodynia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Providers
  • 7.3.3. Spain Vulvodynia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Providers
  • 7.3.4. Italy Vulvodynia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Providers
  • 7.3.5. United Kingdom Vulvodynia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Providers

8. North America Vulvodynia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Providers
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Vulvodynia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Providers
  • 8.3.2. Mexico Vulvodynia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Providers
  • 8.3.3. Canada Vulvodynia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Providers

9. South America Vulvodynia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Providers
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Vulvodynia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Providers
  • 9.3.2. Argentina Vulvodynia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Providers
  • 9.3.3. Colombia Vulvodynia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Providers

10. Middle East and Africa Vulvodynia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Providers
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Vulvodynia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Providers
  • 10.3.2. Saudi Arabia Vulvodynia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Providers
  • 10.3.3. UAE Vulvodynia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Providers

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Vulvodynia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Novartis AG
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.6. SWOT Analysis
• 16.2. Endo International Inc
• 16.3. Teva Pharmaceutical Industries Ltd
• 16.4. Glenmark Pharmaceuticals Ltd
• 16.5. Cipla Inc
• 16.6. F. Hoffmann-La Roche Ltd
• 16.7. Pfizer Inc
• 16.8. Abbvie Inc
• 16.9. Zydus Group
• 16.10.Taro Pharmaceutical Industries Ltd

17. Strategic Recommendations

18. About Us & Disclaimer